Stock CALT CALLIDITAS THERAPEUTICS AB
Add to a list
To use this feature you must be a member
Log inSign up

Highlights Calliditas Therapeutics AB Nasdaq

Equities

CALT

US13124Q1067

Market Closed - Nasdaq
Other stock markets
 04:30:01 2024-05-17 pm EDT 		5-day change 1st Jan Change
22.19 USD +0.73% Intraday chart for Calliditas Therapeutics AB +8.03% -13.81%
May. 16 European Equities Traded in the US as American Depositary Receipts Trend Lower in Thursday Trading MT
May. 15 European Equities Traded in the US as American Depositary Receipts Nudge Higher in Wednesday Trading MT

Highlights

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
European Equities Traded in the US as American Depositary Receipts Trend Lower in Thursday Trading
MT
European Equities Traded in the US as American Depositary Receipts Nudge Higher in Wednesday Trading
MT
European Equities Traded in the US as American Depositary Receipts Nudge Higher in Tuesday Trading
MT
Calliditas Therapeutics Partner Offers Nefecon in China; Shares Rise
MT
European Equities Traded in the US as American Depositary Receipts Trend Modestly Higher in Wednesday Trading
MT
Calliditas Therapeutics' Potential Head and Neck Cancer Treatment Meets Secondary Endpoints
MT
Calliditas Therapeutics AB Announces Positive Topline Results of Phase 2 Head and Neck Cancer Trial with Lead NOX Inhibitor Candidate, Setanaxib
CI
European Equities Traded in the US as American Depositary Receipts Rise Modestly Higher in Thursday Trading
MT
European Equities Traded in the US as American Depositary Receipts Trend Modestly Higher in Thursday Trading
MT
Calliditas Therapeutics AB Announces Positive NefIgArd Open Label Extension Results
CI
European Equities Traded in the US as American Depositary Receipts Trend Higher in Friday Trading But End Week Down
MT
Calliditas Therapeutics Presents Additional Data Analyses from the Phase 3 NeflgArd trial of Nefecon in Primary IgA Nephropathy at the ISN World Congress of Nephrology 2024
CI
Calliditas Therapeutics AB Presents Additional Data Analyses from the Phase 3 NeflgArd Trial of Nefecon in Primary IgA Nephropathy at the ISN World Congress of Nephrology 2024
CI
European Equities Traded in the US as American Depositary Receipts Trend Lower in Wednesday Trading
MT
European Equities Traded in the US as American Depositary Receipts Start Week Higher in Monday Trading
MT
European Equities Traded in the US as American Depositary Receipts Lower in Friday Trading
MT
European Equities Traded in the US as American Depositary Receipts Trend Lower in Tuesday Trading
MT
Calliditas Therapeutics AB to Present Nefecon Data At the ISN World Congress of Nephrology in Buenos Aires
CI
European Equities Traded in the US as American Depositary Receipts Higher in Friday Trading, Close Out Week Lower
MT
European Equities Traded in the US as American Depositary Receipts Trend Higher in Thursday Trading
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. CALTX Stock
  4. CALT Stock
  5. News Calliditas Therapeutics AB
  6. Highlights
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW